Flora Growth (NASDAQ:FLGC) is a diversified agriculture and cannabis company focused on the research, development and commercialization of cannabinoid-based products. Operating under a fully integrated business model, the company cultivates proprietary strains, extracts active compounds and manufactures finished goods for both medical and wellness markets. By leveraging advanced agritech practices and proprietary extraction methods, Flora Growth aims to optimize yield, safety and consistency across its product lines.
The company’s portfolio encompasses a broad range of offerings, including tinctures, topical creams, soft gels and pure cannabidiol (CBD) powders. In addition to its consumer brands, Flora Growth provides white-label and private-label manufacturing services for third-party partners. Its in-house research and development teams focus on formulation science, process optimization and the exploration of lesser-known cannabinoids, positioning Flora Growth at the forefront of product innovation in the evolving cannabis space.
Flora Growth serves markets across North and Latin America, with cultivation facilities in Colombia and Canada. The company also operates e-commerce platforms targeting key markets in the United States and Europe. By combining its international cultivation infrastructure with global distribution channels, Flora Growth seeks to address varying regulatory frameworks and consumer preferences while ensuring product accessibility and regulatory compliance in each jurisdiction.
Founded by a team of agricultural scientists and industry veterans, Flora Growth is led by CEO Hans Hillebrand, whose background spans biotechnology, pharmaceuticals and supply-chain management. Under his leadership, the company has expanded its footprint through strategic partnerships and investments in research collaborations. Flora Growth’s management emphasizes transparency, quality control and sustainable cultivation practices as pillars of its long-term growth strategy in the competitive cannabinoid market.
